Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics Inc. furnished a Form 8-K reporting that on August 11, 2025 the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing includes an Inline XBRL cover page as Exhibit 104. The filing states that the information is furnished and not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except by specific reference. The report identifies the registrant as Denali Therapeutics Inc. (DNLI), incorporated in Delaware and listed on the Nasdaq Global Select Market.
Denali Therapeutics Inc. (Nasdaq: DNLI) filed a Form 8-K to disclose a material regulatory milestone. On July 7, 2025, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Denali’s Biologics License Application (BLA) for tividenofusp alfa, its investigational therapy for Hunter syndrome (MPS II). The news was released via a press release attached as Exhibit 99.1. No financial figures, earnings data, or transactions were included in the filing. The Priority Review designation signals that the agency will evaluate the submission under an expedited pathway, underscoring the product’s potential importance for an underserved patient population. Other than routine exhibit listings and signature blocks, the 8-K contains no additional disclosures.